Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Propofol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.49 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.49 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.49 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.49 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.49 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.49 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.49 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL16340552 | 0.78 | METAP2 (0.47) | HPGDSCN4ACYP2D6ELANE | |
| Proline SCHEMBL16394427 | 0.78 | BLM (0.48) | CYP1A2LMNATSHRBLMSCN4A | |
| SCHEMBL19476115 | 0.77 | KMT2A (0.47) | CYP1A2CYP3A4LMNASCN4ACTSC | |
| SCHEMBL10241519 | 0.76 | SCN4A (0.43) | CYP1A2CYP3A4SCN4ACYP2D6CYP2C19 | |
| SCHEMBL2677256 | 0.76 | SCN4A (0.43) | CYP1A2CYP3A4SCN4ACYP2D6CYP2C19 | |
| Proline SCHEMBL1824936 | 0.75 | SCN4A (0.50) | SLC6A2CYP1A2CYP3A4HPGDTSHR | |
| Proline SCHEMBL1824937 | 0.75 | SCN4A (0.50) | SLC6A2CYP1A2CYP3A4HPGDTSHR | |
| Proline SCHEMBL28101824 | 0.75 | NOS2 (0.40) | CYP1A2CYP3A4BLMSCN4ACTSC | |
| Hydrochloric Acid SCHEMBL6260458 | 0.75 | SCN4A (0.42) | CYP1A2CYP3A4SCN4ACYP2D6CYP2C19 | |
| Biphenyl SCHEMBL2308811 | 0.75 | ELANE (0.47) | CYP1A2CYP3A4LMNAHPGDHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8173840-B2 | Compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC (US) | 2012-05-08 | — | — | US | disclosed |
| WO-2007089745-A2 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | SIGNATURE R & D HOLDINGS, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20060241017-A1 | Novel compounds with high therapeutic index | SIGNATURE R&D HOLDINGS, LLC | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289471-A1 | NOVEL COMPOUNDS WITH HIGH THERAPEUTIC INDEX | IL4I1, SLC7A1, GOT1 | GABRA1 1263/4885GABRB1 1274/4885GABRG2 1915/4885 |
| US-20060241017-A1 | Novel compounds with high therapeutic index | IL4I1, SLC7A1, GOT1 | GABRA1 1263/4885GABRB1 1274/4885GABRG2 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.